Controlled trial of oral 5-aminosalicylic acid for the prevention of early relapse in Crohn's disease
| Autor: | Rodolfo Rocca, Corrado Brignola, Marco Astegiano, L. Framarin, F. A. Riccioli, Gianmichele Meucci, Angelo Pera, C. Belloli, Maurizio Vecchi, R. De Franchis, A. Ferrara, T. Ranzi, Alberto Prada, Paolo Omodei, L. Piodi, M. Del Piano |
|---|---|
| Rok vydání: | 1997 |
| Předmět: |
Adult
Male medicine.medical_specialty Aminosalicylic acid Randomization Adolescent medicine.medical_treatment Placebo Gastroenterology law.invention chemistry.chemical_compound Randomized controlled trial Mesalazine Crohn Disease Double-Blind Method law Internal medicine medicine Secondary Prevention Humans Pharmacology (medical) Treatment Failure Mesalamine Aged Chemotherapy Crohn's disease Hepatology business.industry Anti-Inflammatory Agents Non-Steroidal Middle Aged Interim analysis medicine.disease digestive system diseases Surgery chemistry Female business |
| Zdroj: | Scopus-Elsevier |
| ISSN: | 0269-2813 |
| Popis: | Background Recent data indicate that 5-aminosalicylic acid (5-ASA) is most effective in preventing relapse of Crohn's disease in patients with a short duration of remission before enrolment. Aim To evaluate the efficacy of oral 5-ASA treatment, started immediately after achieving steroid-induced remission, in preventing clinical relapses of Crohn's disease. Methods Patients with active Crohn's disease, achieving remission on steroids, were randomized to oral 5-ASA 3 g/day or placebo, while steroids were tapered over 6 weeks. The trial was terminated after interim analysis showed a slightly higher relapse rate in the 5-ASA group, and the calculated probability of seeing a statistically significant difference by completing the study was minimal. Results Final analysis included 117 patients (58 taking 5-ASA and 59 taking placebo; follow-up 9.2 ± 6.5 months). Cumulative relapse rates at 6 and 12 months were 34% and 58% in 5-ASA patients and 31% and 52% in placebo patients, respectively (rate difference + 0.095; 95% CI = −0.085– + 0.274). Subgroups analysis showed that 5-ASA was equally ineffective in patients with ileal, colonic or ileocolonic disease. Conclusions Contrary to previous results, in our study early introduction of treatment with oral 5-ASA did not prevent relapse in Crohn's disease patients treated with steroids to induce remission. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text